"In Q2, Tempus delivered revenue of $314.6 million, up nearly 90% year over year, and a normalized EPS loss of $0.22, beating estimates by three cents. Genomics revenue surged 115% as oncology testing volumes jumped 26% and hereditary testing climbed 32%, while Data and Insights revenue grew nearly 36% to about $73 million. Management raised its full-year 2025 revenue guidance to $1.26 billion and reaffirmed its forecast for positive $5 million in adjusted EBITDA, an improvement of more than $100 million from last year."
"CEO Eric Lefkofsky said the company is "hitting its stride" approaching its tenth anniversary, noting that Tempus is balancing rapid top-line growth with disciplined investment. Its issuance of $750 million in low-interest convertible notes also strengthened liquidity, leaving the firm well-capitalized as it scales its AI initiatives."
"Tempus' multi-year partnership with AstraZeneca and Pathos to train a large-scale biomedical foundation model is a central narrative. Management said it is running compute across 1,000 H200 GPUs on over 350 petabytes of data -"
Tempus reported exceptional Q2 performance with $314.6 million revenue, nearly 90% year-over-year growth, and a normalized EPS loss of $0.22 that beat estimates. Genomics revenue surged 115% driven by higher oncology and hereditary testing volumes, while Data and Insights revenue grew about 36% to roughly $73 million. Management raised full-year 2025 revenue guidance to $1.26 billion and reaffirmed a $5 million positive adjusted EBITDA target. The company issued $750 million in low-interest convertible notes to bolster liquidity. A multi-year partnership with AstraZeneca and Pathos targets a large biomedical foundation model using extensive GPU compute and petabyte-scale data. Analysts expect margin improvement and potential breakeven by early 2026.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]